Загрузка...
Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
This 19-week, double-blind, placebo-controlled, randomized phase 2 study evaluated the efficacy, safety, and tolerability of adjunctive cariprazine (0.1–0.3 and 1.0–2.0 mg/day) as an antidepressant treatment for adults with treatment-resistant major depressive disorder (MDD) (NCT00854100). The prima...
Сохранить в:
| Опубликовано в: : | Int Clin Psychopharmacol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Lippincott Williams And Wilkins
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166709/ https://ncbi.nlm.nih.gov/pubmed/30045066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000235 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|